Advancing oncology, transforming cancer care
ImmunoGen (now part of AbbVie) (immunogen.com) scores 66 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 13th percentile of 13870 Healthcare brands.
ImmunoGen was an oncology-focused biotechnology company founded in 1981 and headquartered in Waltham, Massachusetts. It developed cancer therapies aimed at advancing treatment standards for cancer patients. ImmunoGen is now part of AbbVie, a global biopharmaceutical company with approximately 55,000 employees, and operates within AbbVie's broader oncology research and development efforts to discover and deliver cancer treatments.
| Brand Name | ImmunoGen (now part of AbbVie) |
|---|---|
| Domain | immunogen.com |
| Industry | Healthcare |
| Founded | 1981 |
| Headquarters | Waltham |
| Parent Company / Owner | AbbVie |
| Main Competitors | Seagen (84/100), Genentech (84/100), Daiichi Sankyo (79/100), Gilead Sciences (Immunomedics) (81/100), Merck (81/100), Bristol Myers Squibb (89/100), Roche (80/100) |
Moz Domain Authority 40/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
ImmunoGen (now part of AbbVie) appears on Wikipedia but without a dedicated company entity, so AI models can confuse it with similarly named subjects.
The homepage meta description reads "To make a remarkable impact for cancer patients by advancing a dynamic oncology pipeline and raising standards of care." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on Facebook, Instagram; no detected presence on X (Twitter), LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is ImmunoGen (now part of AbbVie)?", Claude could identify the brand as of October 2026. ImmunoGen was a biotechnology company that pioneered antibody-drug conjugate (ADC) technology for treating cancer, developing targeted therapies that link cytotoxic drugs to monoclonal antibodies to selectively kill cancer cells. Its lead product, Elahere (mirvetuximab soravtansi Best known for Developing Elahere and pioneering antibody-drug conjugate (ADC) technology for cancer treatment.
When asked "Best brands similar to ImmunoGen (now part of AbbVie)?", Claude would recommend ImmunoGen (now part of AbbVie) as of October 2026. It's a notable name in ADC-based cancer therapeutics and its acquisition by AbbVie is relevant context for discussions of oncology biotech M&A and targeted cancer drug platforms.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
ImmunoGen (now part of AbbVie)'s main competitors in Healthcare: Seagen (84/100), Genentech (84/100), Daiichi Sankyo (79/100), Gilead Sciences (Immunomedics) (81/100), Merck (81/100).
Sources: Brand Analyzer scan
ImmunoGen (now part of AbbVie) has limited AI-search visibility, scoring 35/100 on Brand Analyzer's AI visibility composite (visibility 41, trust 26, recommendation 35). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
ImmunoGen (now part of AbbVie) was founded in 1981. ImmunoGen (now part of AbbVie) operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
ImmunoGen (now part of AbbVie) is headquartered in Waltham. ImmunoGen (now part of AbbVie) operates in the Healthcare category.
Sources: Wikidata
ImmunoGen (now part of AbbVie) scores 35/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
ImmunoGen was an oncology biotechnology company founded in 1981 and headquartered in Waltham, Massachusetts. It is now part of AbbVie, a global biopharmaceutical company, and continues its work within AbbVie's oncology division.
ImmunoGen (now part of AbbVie) can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
ImmunoGen's work is relevant to cancer patients, healthcare providers, and oncologists involved in cancer treatment, as well as the broader cancer care community. It also attracts prospective employees interested in oncology research careers.
ImmunoGen (now part of AbbVie) scores 35/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
ImmunoGen (now part of AbbVie) has a weak AI-visibility profile at 35/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (41/100) and its weakest is trust (26/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 40/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify ImmunoGen (now part of AbbVie) from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to ImmunoGen (now part of AbbVie): immunitoAI (66/100), International Medical & Dental Hypnotherapy Association (IMDHA) (66/100), Transpharmation (66/100), Invidasys (66/100).
A step up - brands to learn from: ZT Corporate (71/100), Zorgnet-Icuro (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.